Q2 EPS Forecast for Assembly Biosciences Lifted by Analyst

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities research analysts at HC Wainwright lifted their Q2 2026 EPS estimates for shares of Assembly Biosciences in a research report issued to clients and investors on Wednesday, May 13th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings per share of ($0.70) for the quarter, up from their prior estimate of ($0.71). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Assembly Biosciences’ FY2026 earnings at $1.90 EPS, Q2 2027 earnings at ($1.18) EPS, Q3 2027 earnings at ($1.18) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at $0.23 EPS and FY2029 earnings at ($3.10) EPS.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.11. The firm had revenue of $8.21 million during the quarter, compared to analyst estimates of $9.27 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%.

Several other research firms have also weighed in on ASMB. Guggenheim lifted their target price on shares of Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a report on Monday, April 6th. Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Assembly Biosciences Price Performance

NASDAQ:ASMB opened at $27.42 on Tuesday. The firm has a market cap of $435.79 million, a price-to-earnings ratio of -249.25 and a beta of 1.08. The company has a 50 day moving average price of $28.76 and a 200-day moving average price of $30.58. Assembly Biosciences has a 1-year low of $13.13 and a 1-year high of $39.71.

Institutional Investors Weigh In On Assembly Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC purchased a new stake in Assembly Biosciences in the 3rd quarter worth $31,426,000. RA Capital Management L.P. purchased a new stake in Assembly Biosciences in the 3rd quarter worth $26,122,000. Commodore Capital LP purchased a new stake in Assembly Biosciences in the 3rd quarter worth $25,600,000. Janus Henderson Group PLC increased its holdings in Assembly Biosciences by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock worth $23,479,000 after acquiring an additional 11,384 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP purchased a new stake in Assembly Biosciences in the 4th quarter worth $22,625,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.